NCT00085202 - Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor | Biotech Hunter

Enrollment

416

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2023

Conditions

Brain and Central Nervous System Tumors

Interventions

BIOLOGICAL

filgrastim

Given subcutaneously

DRUG

cisplatin

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

vincristine

Given IV

PROCEDURE

autologous hematopoietic stem cell transplantation

Patients undergo autologous stem cell transplantation

RADIATION

radiation therapy

Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.

Trial Locations (9)

2031

Sydney Children's Hospital, Randwick

2145

Children's Hospital at Westmead, Westmead

3052

Royal Children's Hospital, Parkville

4029

Lady Cilento Children's Hospital, Brisbane, Brisbane

19104

Children's Hospital of Philadelphia, Philadelphia

27710

Duke Comprehensive Cancer Center, Durham

38105

St. Jude Children's Research Hospital, Memphis

77030-2399

Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston

M5S 0A4

Hospital for Sick Children, Toronto

All Listed Sponsors

lead

St. Jude Children's Research Hospital

OTHER